Nippon Zenyaku Kogyo Co Ltd
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Nippon Zenyaku Kogyo Co Ltd
Pfenex founder and chief business officer Patrick Lucy has left the company to join Lykan Bioscience. Meanwhile, Samsung Biologics has announced the appointment of a new president and CEO, as the Australian generics and biosimilars association appoints a new chair.
Although there weren’t many large-scale partnerships as in previous years, Korean biopharma firms were involved in a broad range of deals across diverse therapeutic areas in 2020, with ADCs, oncology and domestic alliances emerging as key trends.
As Apotex names its new US president and CEO, Akorn puts together a fresh board of directors following bankruptcy proceedings. Stada has made new appointments in Germany, while Siegfried makes significant changes in its leadership roles.
Endo is leaving the door wide open to settle its patent-litigation showdown with Eagle Pharmaceuticals over Vasostrict (vasopressin), after Eagle said it was mulling an ‘at-risk’ launch.
- Drug Discovery Tools
- Other Names / Subsidiaries
- Zenyaku Kogyo Co., Ltd.